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Summary
Background.— The Eplerenone Post-Acute Myocardial Infarction Heart Failure Efﬁcacy and Sur-
vival Study (EPHESUS) randomized clinical trial demonstrated the efﬁcacy of eplerenone, a new
aldosterone antagonist diuretic, with standard treatment versus standard treatment alone in
the reduction of cardiovascular mortality and cardiovascular-related hospital readmissions for
patients with heart failure after an acute myocardial infarction.
Aim.— We assessed the incremental cost per life-year saved of eplerenone in the French context
versus standard treatment.
Methods.— A within-trial study was designed. A piecewise regression model yielded death rates
and survival gains adjusted for patients’ characteristics, based on the extraction of comparable
patients from the Saskatchewan Health database. Resource use was collected alongside the
clinical trial data. Only direct medical costs were considered. All costs were in 2003 euros.
Costs and outcomes were discounted at 5%.
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Insufﬁsance
cardiaque ;
Infarctus du
myocarde aigu ;
Prévention
Conclusion.— Éplérénone entraîne un niveau acceptable de coût incrémental par année de vie
gagnée comparé aux traitements existants de prévention de la morbimortalité cardiovasculaire
chez les patients insufﬁsants cardiaques post-IM aigu.
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ackground
n Europe, the prevalence of heart failure (HF) varies from
.4 to 2% [1,2]. In France, the prevalence of patients with
F was estimated to be 500,000 in 1998, with an annual inci-
ence of 120,000 [3]. Forty per cent of patients die within
2 months of the diagnosis, and only 25% of men and 38% of
omen survive for ﬁve years. The incidence and prevalence
f severe HF, deﬁned as left ventricular ejection fraction
LVEF) less than 30% and a cardiothoracic index greater than
0%, are known through Épidémiologie de l’insufﬁsance car-
iaque avancée en Lorraine (EPICAL), a study performed in
orraine, an eastern region of France [4]. The incidence was
ound to be 225 cases per one million inhabitants, which,
hen extrapolated to the whole of France, yields an esti-
ated 13,500 new cases of severe HF per year. The incidence
ncreased substantially with advancing age, with two-thirds
f patients being over 70 years. In 1999, 28,200 deaths were
ttributable to HF [5]. HF is the cause of 150,000 hospital
dmissions and 3.4million visits per year [3].
The presence of acute myocardial infarction (AMI)
ncreases the risk of HF, particularly in the ﬁrst days after
he ischaemic event. According to the Valsartan in Acute
H
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yocardial Infarction (VALIANT) registry, 20% of all patients
ith AMI presented signs and symptoms of HF during hos-
ital stay [6]. The Cholesterol and Recurrent Events (CARE)
tudy found that 22% of patients with an AMI had acute HF;
ncidence of HF for patients with recurrent AMI was 33%
7]. According to Cowie, the rate of HF as a direct conse-
uence of AMI is 19% [2]. USIK is a French study in patients
dmitted for an AMI [8]. In this study, 45% of patients had
linically established HF. When extrapolating the data to the
hole of France, knowing that 100,000 cases of AMI are reg-
stered, the number of patients with HF after an AMI can be
stimated at between 19,000 and 45,000 per year.
Patients with HF consecutive to an AMI receive secondary
revention treatment, combining angiotensin-converting
nzyme (ACE) inhibitors with diuretics and/or beta-blockers
9]. The Randomized Aldactone Evaluation Study (RALES)
ortality trial showed that the administration of low-dose
pironolactone, a diuretic with an aldosterone-antagonist
ffect, reduced mortality of post-AMI patients with severeG. de Pouvourville et al.
Results.— The overall mortality rate was 14.4% in the treatment group versus 16.7% in the
placebo group (p = 0.008). Combined cardiovascular deaths and hospitalization rates were 26.7%
in the treatment group versus 30.3% in the placebo group (p = 0.002). The discounted survival
gain was 3.2 weeks. The incremental cost per life-year saved was D 15,382 (95% conﬁdence inter-
val 8274—42,723). Seventy-four per cent of the values of the incremental cost-effectiveness
ratio fell under a D 15,000 per life-year saved threshold.
Conclusion.— The cost of eplerenone leads to an acceptable level of incremental cost per
life-year saved when compared with existing treatments in the cardiovascular domain for the
prevention of cardiovascular death and morbidity in patients with heart failure after an acute
myocardial infarction.
© 2008 Elsevier Masson SAS. All rights reserved.
Résumé
Contexte.— L’essai EPHESUS a démontré l’efﬁcacité d’éplérénone, un nouveau diurétique
antagoniste de l’aldostérone, avec un traitement standard, comparé au traitement standard
seul, dans la réduction de la mortalité et du taux de réhospitalisation cardiovasculaires chez
des patients insufﬁsants cardiaques après infarctus aigu du myocarde.
Objectifs.— Le coût incrémental d’éplérénone par année de vie gagnée comparativement au
traitement standard a été calculé en France.
Méthode.— Une étude intra-essai a été réalisée. Les taux de mortalité et les gains de survie
ajustés aux caractéristiques des patients ont été modélisés sur une population de patients
comparables du Saskatchewan (Canada). Les données d’utilisation de ressources proviennent
de l’essai. Seuls les coûts médicaux ont été valorisés, en euros (2003). Les coûts et les effets
ont été actualisés à 5 %.
Résultats.— La mortalité globale était de 14,4 % dans le groupe traité contre 16,7 % dans le
groupe placebo (p = 0,008). Le taux combiné d’hospitalisation et de décès cardiovasculaires
était de 26,7 % avec contre 30,3 % sans (p = 0,002). Le gain actualisé de survie était de 3,2
semaines, le coût par année de vie gagnée de 15 382D (IC à 95% : 8274D—42 723D ). Soixante-
quatorze pour cent des valeurs du ratio coût par année de vie gagnée étaient inférieures à
15 000D .F [10]. With spironolactone, however, 10% of men suf-
er from painful gynaecomastia that may justify stopping
reatment. Eplerenone is an aldosterone antagonist that
educes the risk of gynaecomastia. Eplerenone Post-Acute
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ePrevention of CV events for post-AMI heart failure
Myocardial Infarction Heart Failure Efﬁcacy and Survival
Study (EPHESUS) was a randomized controlled trial compar-
ing the combination of eplerenone plus standard treatment
versus standard treatment alone for secondary prevention
of severe cardiovascular events and death for patients with
AMI and HF [11]. In this trial, overall mortality was reduced
by 15% and cardiovascular rehospitalizations and cardiovas-
cular deaths were reduced by 13%.
The aim of the present study was to calculate the relative
cost-effectiveness of eplerenone plus standard treatment
versus standard treatment alone in the French context.
Methods
Patient population
The EPHESUS trial included 6632 patients with post-AMI HF,
with a mean follow-up of 16 months. Patients were ran-
domized to either standard optimal treatment including
ACE inhibitors, angiotensin II receptor blockers, diuretics,
statins, beta-blockers, or coronary reperfusion plus 25mg
eplerenone (titrated up to 50mg/day), or a placebo plus
standard optimal treatment (control group).
The economic analysis was a within-trial analysis since
no data were available on the evolution of the patients’
health status beyond the mean 16-month follow-up period
or on the efﬁcacy of treatment. In EPHESUS, the primary
endpoints were time to all-cause death or cardiovascular
death and ﬁrst hospitalization for any cardiovascular event.
The main secondary endpoints were cardiovascular death
and all-cause death, and any hospitalization.
Survival
The results from EPHESUS were used to model the expected
number of life-years gained with the reduction of overall
mortality through the follow-up period. The model used in
our study was based on the original cost-effectiveness analy-
sis performed by Weintraub et al. [12] in the USA, with minor
modiﬁcations that did not alter signiﬁcantly the projections
of life-years saved.
Two alternative methods were used to predict long-term
survival of patients. First, a sample of 2543 patients with HF
after an AMI was extracted from the Saskatchewan Health
database. Piecewise regressions were used to estimate
mortality risk functions over time and thus survival. Adjust-
ment of survival to patients’ characteristics was obtained
using proportional hazard Cox models. Piecewise regressions
were used because the observed mortality did not follow a
decreasing exponential: mortality was high during an acute
period after initial event, then tended to stabilize, and
ﬁnally to increase again because of aging. Moreover, disper-
sion in the acute phase was not high, but tended to increase
through time. Second, the Framingham equation was used
to compute expected survival for patients included in the
EPHESUS trial.Life-years lost for patients who died during the trial
were calculated as a difference between age at death and
age- and sex-speciﬁc life expectancies derived from the
two methods of survival estimations. Patients who survived
during the trial duration did not yield any difference in life-
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ears saved between eplerenone and placebo. A stochastic
ensitivity analysis was performed on the difference in the
umber of life-years gained between both groups, using
aive bootstrap. A conﬁdence interval (CI) was also esti-
ated for the incremental cost-effectiveness ratio (ICER)
nd acceptability curves were established.
osts
nly direct medical costs were considered in the model,
dopting for France a partial societal perspective. Events
nd related healthcare services were collected along-
ide the clinical trial data. For hospitalizations, patients’
ecords were classiﬁed in the initial north-American cost-
ffectiveness study using USA diagnosis-related groups
DRGs). Mapping to the French DRG classiﬁcation was per-
ormed. When mapping was possible, the French costs per
RGs were obtained through the National Cost per Stay Sur-
ey, which provides for an average full cost per stay in the
ublic sector [13,14]. For a minority of DRGs and cases,
apping was not possible. We then used Schulman et al.’s
ethod to estimate a cost for France [15]. First, we com-
uted an overall conversion rate between US and French
osts for DRGs for which mapping was possible. The conver-
ion rate was the ratio for all cases of US cost per DRG
eighted by the number of cases in the trial, to the French
osts per DRG weighted by the number of cases. The conver-
ion rate then was applied to the US costs for the DRGs for
hich mapping was not possible.
Diagnostic procedures and visits to physicians were val-
ed using charges obtained from the French National Fee
chedule. For procedures that could not be mapped into
he French procedure code, the conversion rate methodol-
gy was applied. Drugs were costed using the French Public
rices for 2003. The daily treatment cost for eplerenone
as D 2558. Costs and outcomes were discounted at a
% rate, following the recommendations of the French
ealth Economists Association [16]. All costs are in 2003
uros.
esults
linical outcomes
he overall mortality over the trial period was 478 (14.4%)
atients in the treatment group versus 554 (16.7%) in the
lacebo group (p = 0.008). Combined cardiovascular deaths
nd hospitalizations were 885 (26.7%) in the treatment
roup versus 993 (30.3%) in the placebo group (p = 0.002)
Table 1).
ife-years gained
sing the Saskatchewan database, 20 weeks of life are
ost with standard treatment plus placebo versus 17 for
plerenone plus standard treatment. Thus, long-term undis-
ounted survival is three weeks. Using the Framingham
atabase, 32 weeks of life are lost for patients who receive
tandard treatment only versus 27 weeks for patients
reated with eplerenone: the incremental effectiveness is
ve weeks (Table 2).
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Table 1 EPHESUS endpoints and results.
Eplerenone (n = 3319) Placebo (n = 3313) Relative risk (95% CI) p
Primary endpoints 478 (14.4%) 554 (16.7%) 0.85 (0.75—0.96) 0.008
Death from any cause, n (%)
Death or hospitalization for
cardiovascular events, n (%)
885 (26.7%) 993 (30.3%) 0.87 (0.79—0.95) 0.002
Secondary endpoints 407 (12.3%) 483 (14.6%) 0.83 (0.72—0.94) 0.005
Death from cardiovascular
causes, n (%)
Table 2 Life-years lost life, discounted at 5%: Eplerenone versus placebo.
Placebo (n = 3313) Eplerenone (n = 3319) Gain 95% conﬁdence interval
Discounted life-years lost
Saskatchewan data 0.3653 0.3032 −0.0620 −0.1015, −0.0224
Framingham data 0.6137 0.5165 −0.0972 −0.1652, −0.0315
Table 3 Resource use during follow-up.
Event, n Eplerenone + standard treatment Placebo + standard treatment p
Hospitalizations — all cause 2815 2984 0.12
Hospitalization for cardiovascular events 876 1004 0.03
Acute myocardial infarction 268 269 0.19
Heart failure 477 618 0.002
Stroke 73 54 0.73
Ventricular arrhythmia 58 63 0.79
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fEmergency room visits 1004
Cardiovascular diagnostic procedures 1.64
esource use during follow-up
able 3 displays the results for hospital-resource use.
n the treatment group, there were 169 fewer hos-
ital admissions for all causes, 128 fewer admissions
or cardiovascular causes, the same number of cardio-
ascular diagnostic procedures, and 112 fewer visits to
mergency rooms. Thus, a slight reduction in resource
se was observable with eplerenone, but the differ-
nce was signiﬁcant only for hospital admissions for
F.
o
t
t
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Table 4 Average cost in euros per patient during follow-up pe
Item, D Placebo (n = 3313) Ep
Rehospitalization costs 3473 ± 5.856
Medication costs 1082 ± 885 10
Outpatient diagnostic procedure
costs
239 ± 719 2
Emergency room visit costs 20.5 ± 57.0
Eplerenone costs (D 2.511/day) 0 10
Total follow-up costs (including
cost of eplerenone)
4814.1 ± 6287.5 57
* Bilateral Student’s t test.1116 0.1
1.67 0.34
osts during follow-up period
he total undiscounted direct medical cost of follow-up dur-
ng the trial period, excluding the cost of eplerenone, was
4698.7 for the treatment group versus D 4814.1 for the
lacebo group. Eplerenone added an extra cost of D 1084.9
or the period of treatment. Costs for rehospitalizations and
utpatient diagnostic procedures were slightly lower in the
reatment group versus the placebo group. The most impor-
ant differences in costs were observed for hospitalizations
or cardiovascular causes and for HF (Table 4).
riod: eplerenone versus placebo (no discount).
lerenone (n = 3319)  (Eplerenone—placebo) p*
3337 ± 5503 −135.7 0.17
90.4 ± 864 −8.3 0.29
52.9 ± 646 14.0 0.14
18.6 ± 48.7 −1.9 0.075
84.9 ± 573.4
83.6 ± 5963.4 969.6 0.12
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Table 5 Cost-effectiveness analysis using different discount rates for costs and life years: Saskatchewan and Framingham
survival models (with cost D 2558/day).
Placebo
(D )
Eplerenone
(D )
 cost  life
years
ICER 95% CI Percentage <D 50,000/
life year gained
Saskatchewan
No discount 4814 5784 970 0.066 14.672 7903, 41.004 97.9
5% discount 4767 5721 954 0.062 15.382 8274, 42.723 97.9
Framingham
No discount 4814 5784 970 0.108 8954 4639, 27.909 98.7
5% discount 4767 5721 954 0.097
Incremental cost-effectiveness ratio
The baseline estimation was made using a 5% discount rate
for costs and outcomes. The extra cost per life-year saved
was D 15,382 (95% CI 8274—42,723) when using the esti-
mation model derived from the Saskatechewan database.
With no discounting, the ICER with the Saskatchewan data
dropped to D 14,672 per year-of-life saved, and D 9819 (95%
CI 5159—30,178) using the Framingham data to estimate sur-
vival (Table 5).
Stochastic sensitivity analysis
A stochastic sensitivity analysis of the ICER was performed
to obtain an acceptability curve using bootstrapping and
5000 iterations. Assuming a willingness to pay of D 15,000
per life year, treatment with eplerenone is accepted in 74%
of all cases, and in 99% of all cases with a willingness to pay
D 50,000 (Saskatchewan estimation of survival, costs, and
beneﬁts discounted 5%) (Fig. 1).
Figure 1. Acceptability curve: Saskatchewan survival data, dis-
count 5%. Cost in D , cost per year of life saved.
Courbe d’acceptabilité : données de survie de la Saskatchewan,
actualisation de 5%. Coût en D , coût par année de vie gagnée.
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iscussion
he adoption of a within-trial analysis does not allow for full
ssessment of the cost-effectiveness of the intervention. In
eal life, patients would probably continue treatment for
heir lifetime. This choice is always a question of trade-off
etween the face validity of the extrapolation of outcome
nd the cost results for the intervention through time and
he limits of a censored analysis. In particular, the model
ay be very sensitive to assumptions made not only on death
ut also on hospitalization and outpatient procedures, which
s why we chose a restrictive model.
In this particular case, outcomes in terms of survival have
lready been stretched further than the duration of the
rial, using either complex modelling from the Saskatchewan
atabase or with the Framingham data. Because the Fram-
ngham data were related to patients with HF, and not
peciﬁcally HF after AMI, the overall gain in survival may
ave been overestimated. Patients in the Saskatchewan
atabase were similar to those from the EPHESUS trial and
he ‘piecewise’ estimation of the probabilities of death
llowed for a better adjustment of survival to the patients’
haracteristics. Thus, the true cost-effectiveness ratio may
e closer to the estimation obtained with the Saskatchewan
ata.
The overall cost of treatment between the two groups
as very similar. There is little potential for cost-
aving, although patients treated with eplerenone tend to
xperience fewer hospital readmissions, and have fewer
utpatient diagnostic procedures and emergency room vis-
ts, which has some impact on quality of life. Compared
o the study by Weintraub et al. [12], we did not use
he Worcester Heart Attack Registry because we wanted
o keep a conservative approach to estimation of the
ost-effectiveness ratio, and the Saskatchewan database
elivered the lowest differences in estimates of life-years
ost between the two branches. We did not estimate quality-
djusted life years because the data were from only a small
ubsample of French patients. Moreover, no French value
as yet been set for health states described by EQ-5D, the
uestionnaire used in the trial.
The exclusion of indirect costs, in particular days out
f work, should have little impact on the results since the
atients’ average age in the EPHESUS trial was 64 years and
large proportion would therefore have retired.
Schulman et al.’s [15] conversion method could carry a
ias if the admissions or procedures for which there is no
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[20
irect mapping between US and French DRGs or procedure
odes are very different in terms of relative costs between
he two countries. In this study, this bias exists but has a
ery low impact, since mapping was impossible for less than
% of all events.
The relatively high variance in the ICER is probably
elated to the fact that the efﬁcacy of the treatment was
hort term. The modelling of long-term survival plausibly
dds dispersion, since mortality tends to be less predictable
ith increasing age.
The actual cost per-life year saved (D 15,382) can be com-
ared to the cost-effectiveness ratio of other interventions.
cost-utility analysis from the RALES mortality trial has
een performed, comparing spironolactone with standard
reatment to placebo with standard treatment for the sec-
ndary prevention of cardiovascular events and deaths for
atients with a severe HF (LVEF < 35%) after an AMI [17].
he follow-up period was 35 months. The study found that
esults ranged from cost-savings to a maximum cost per
uality-adjusted life year of $US 20,300. The difference with
plerenone can be explained by the low price of spironolac-
one, which had been on the market for a long time when
he trial was performed, by the selection of a high-risk pop-
lation, and by the duration of follow-up. This suggests that
he cost-effectiveness ratio of eplerenone may be improved
f targeted towards patients with severe HF. The RALES eco-
omic evaluation study did not include a valuation of the
ain secondary effect of spironolactone, which was painful
ynaecomastia, which eplerenone reduces signiﬁcantly.
Using CODECS, the French documentary database on
ealth-economic evaluation, eight cost-effectiveness stud-
es were selected in the cardiovascular ﬁeld with results
n terms of cost per life-year saved. Full comparison with
he results from the present study must be interpreted
ith caution: it requires some actualization for prices and
otential improvements in technology. Moreover, older stud-
es seldom comprise a stochastic sensitivity analysis on the
ost-effectiveness ratio and thus do not publish conﬁdence
ntervals. Published data nevertheless give a relevant order
f magnitude. For example, the cost per life-year saved of
eart transplantation was D 17,626 in 1992 in France [18].
he ICER of recombinant tissue plasminogen activator ver-
us streptokinase for the prevention of thrombotic events
n the acute phase of AMI was D 12,190 in 1994 [19]. Thus,
econdary prevention of cardiovascular events and deaths
or post-AMI patients with eplerenone and a standard treat-
ent compares at least with two well-accepted treatments
n France.
In the USA, and with a 3% discount rate, the incre-
ental cost per life-year saved was $US 21,876 (D 17,304
sing the July 2006 exchange rate) [12]. Croom and Plosker
5] reviewed existing economic studies performed in other
ountries, and a Swiss study has since been published. All use
he same model structure, and their conclusions are quite
imilar. In Germany, the ICER ranged from D 6956 to D 14,628
ccording to the different scenarios [5]. In Spain, the dis-
ounted ICER with the Saskatchewan scenario was D 11,530
20]. In the Netherlands, according to Croom and Plosker [5],
he ICER ranged from D 5635 to D 12,795. Finally, in Switzer-
and, the discounted ICER for the Saskatchewan scenario was
HF 16,178 (D 10,392 using the July 2006 exchange rate)
21]. Differences in ICER tell us more about differences in
[
[G. de Pouvourville et al.
ost level and structure in the different countries than about
ifferences in cost-effectiveness per se. But in all countries,
he ICERs compare favourably to those of other accepted
nterventions.
onclusion
ombining the standard treatment of HF after an AMI with
n aldosterone-blockade drug, eplerenone, is effective in
reventing overall mortality, cardiovascular mortality, and
ehospitalizations. The gain in survival over the long term
s modest, but the incremental cost of eplerenone leads to
n acceptable level of incremental cost per life-year saved
hen compared to existing treatments in the cardiovascular
eld.
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